Hayden E. Klein

There seems to be an institutional ignorance toward social determinants of health and actually making changes to improve outcomes for patients of color, said Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust.

The EMPEROR trial showed that within 30 days of stopping empagliflozin, patients had a 70% higher risk of heart failure events, explained Milton Packer, MD, Baylor University Medical Center.

Nikolaus Marx, MD, professor of medicine/cardiology and head of the Department of Internal Medicine, University Hospital Aachen, Germany, explains the new guidelines on screening for patients with type 2 diabetes and comorbid cardiovascular disease (CVD).

When determining the success of cardiology therapies, trials should focus more on softer end points like quality of life and psychological well-being, said Donna Fitzsimons, PhD, FESC, professor of nursing at the School of Nursing and Midwifery, Queen's University Belfast.

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, professor of medicine at the University of Queensland.

With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.

Attendees should look out for results from the STEP HFpEF program and HEART-FID trial at the European Society of Cardiology (ESC) Congress 2023, said Stephen Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.

Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology landscape and improving patient access to guideline-recommended treatments.

Ahead of the European Society of Cardiology (ESC) Congress 2023, John McMurray, MD, FRCP, FESC, professor of medical cardiology at the University of Glasgow, previews some themes and important topics that will be discussed at the meeting.

The decrease in e-cigarette use between 2014 and 2019 may be linked to improved education on the harms of the devices, while the increase in 2019 could be attributed to worsened psychological burden during the COVID-19 pandemic.

New research demonstrated varying trends in early-onset cancer incidence based on race, sex, age, and cancer type.

New research found that ovarian cancer risk is reduced by salpingectomy just as much as by tubal ligation, contradicting guidelines that suggest otherwise.

According to one panelist, the leading causes of hypoglycemia in older adults are insufficient nutrition and taking the wrong dose or type of insulin, both of which can be addressed at the patient and system level.

While there is currently no effective treatment for chemotherapy-induced peripheral neuropathy, one of the most common and severe adverse effects for patients who have undergone chemotherapy for ovarian cancer, a 6-month aerobic exercise intervention significantly improved symptoms.

New research shows that in vitro fertilization with or without intracytoplasmic sperm injection and the use of fresh or frozen embryo transfers were not associated with an increased risk of cardiovascular disease (CVD) for the mother.

Using data from the Swedish National Medical Birth Register, researchers found that different neurocutaneous syndromes are associated with increased risk of childhood cancer, especially central nervous system tumors.

Postpartum cardiovascular health counseling dropped slightly from 2016 to 2020, both for individuals with and without cardiovascular disease risk factors.

A Hong Kong study revealed how much type 2 diabetes (T2D) can increase hospital bed-days based on condition, age, sex, and other factors.

Mount Sinai researchers discovered a 64-protein signature that may help predict whether patients with high-grade serous ovarian cancers will respond to chemotherapy.

Panelists at the American Diabetes Association 83rd Scientific Sessions explained how time in range is emerging as a crucial target in diabetes management.

In his explanation of the tremelimumab priming dose, Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, also reviews and analogizes checkpoint inhibitors as a whole.

Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.

G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.

Coverage of ASCO sessions and posters that addressed lessons from the Oncology Care Model and concerns about the Enhancing Oncology Model, which launched shortly after the annual meeting ended.

Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, expands on findings that durvalumab plus tremelimumab demonstrated an overall survival benefit at 4 years for certain patients with unresectable hepatocellular carcinoma.

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

Among people living with HIV receiving antiretroviral therapy, those taking 4-mg pitavastatin daily were 35% less likely than those taking placebo to experience a major cardiovascular event over 5 years of follow-up.

New research suggests that when cancer cells are under stress, cellular chaperone protein GRP78 alters its behavior and migrates to the cell's nucleus, where it modifies gene activities and allows cancer cells to become more mobile and invasive.

After replicating the PURE study, researchers found that individuals with higher PURE diet scores had lower risk of death, cardiovascular disease, myocardial infarction, and stroke.

The biggest barriers in collaboration are communication and connectivity, said Susan Escudier, MD, FACP, vice president of value-based and quality programs for Texas Oncology.